<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39351230</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium.</ArticleTitle><Pagination><StartPage>1371156</StartPage><MedlinePgn>1371156</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1371156</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1371156</ELocationID><Abstract><AbstractText>Effective treatment and immunoprophylaxis of viral respiratory infections with neutralizing monoclonal antibodies (mAbs) require maintaining inhibitory concentrations of mAbs at the airway surface. While engineered mAbs with increased affinity to the neonatal Fc receptor (FcRn) are increasingly employed, little is known how increased affinity of Fc to FcRn influences basal-to-apical transepithelial transport (transcytosis) of mAbs across the airway epithelium. To investigate this, we utilized a model of well-differentiated human airway epithelium (WD-HAE) that exhibited robust FcRn expression, and measured the transepithelial transport of a mAb against SARS-CoV-2 Spike protein (CR3022) with either wildtype IgG<sub>1</sub>-Fc or Fc modified with YTE or LS mutations known to increase affinity for FcRn. Despite the marked differences in the affinity of these CR3022 variants for FcRn, we did not find substantial differences in basal-to-apical transport reflective of systemic dosing, or apical-to-basal transport reflective of inhaled dosing, compared to the transport of wildtype IgG<sub>1</sub>-Fc. These results suggest increasing FcRn affinity may only have limited influence over transcytosis rates of systemically dosed mAbs across the human airway epithelium over short time scales. Over longer time scales, the elevated circulating levels of mAbs with greater FcRn affinity, due to more effective FcRn-mediated recycling, may better resupply mAb into the respiratory tract, leading to more effective extended immunoprophylaxis.</AbstractText><CopyrightInformation>Copyright © 2024 Togami, Wolf, Olson, Card, Shen, Schaefer, Okuda, Zeitlin, Pauly, Whaley, Pickles and Lai.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Togami</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Whitney</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Lucas C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Card</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Limei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaefer</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuda</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeitlin</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ZabBio, San Diego, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauly</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ZabBio, San Diego, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whaley</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>ZabBio, San Diego, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickles</LastName><ForeName>Raymond J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Samuel K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011961">Receptors, Fc</NameOfSubstance></Chemical><Chemical><RegistryNumber>TW3XAW0RCY</RegistryNumber><NameOfSubstance UI="C100688">Fc receptor, neonatal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011961" MajorTopicYN="Y">Receptors, Fc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="Y">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="Y">Transcytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020545" MajorTopicYN="Y">Respiratory Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FcRn</Keyword><Keyword MajorTopicYN="N">airway</Keyword><Keyword MajorTopicYN="N">lung</Keyword><Keyword MajorTopicYN="N">monoclonal Abs</Keyword><Keyword MajorTopicYN="N">respiratory virus</Keyword><Keyword MajorTopicYN="N">transcytosis</Keyword></KeywordList><CoiStatement>Authors LZ, MP, and KW were employed by the company ZabBio. Author SL is founder of Mucommune, LLC and currently serves as its interim CEO. Author SL is also founder of Inhalon Biopharma, Inc, and currently serves as its CSO as well as on its Board of Director and Scientific Advisory Board. Author SL has equity interests in both Mucommune and Inhalon Biopharma; Author SL’s relationships with Mucommune and Inhalon are subject to certain restrictions under university policy. The terms of these arrangements are managed by UNC-CH in accordance with its conflict-of-interest policies. Author SL was inventor of intellectual property that has been licensed to Inhalon Biopharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351230</ArticleId><ArticleId IdType="pmc">PMC11439726</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1371156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. . Sars-cov-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. (2020) 182:429–46.e14. doi: 10.1016/j.cell.2020.05.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.042</ArticleId><ArticleId IdType="pmc">PMC7250779</ArticleId><ArticleId IdType="pubmed">32526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol. (2005) 79:8651–4. doi: 10.1128/JVI.79.13.8651-8654.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.13.8651-8654.2005</ArticleId><ArticleId IdType="pmc">PMC1143745</ArticleId><ArticleId IdType="pubmed">15956607</ArticleId></ArticleIdList></Reference><Reference><Citation>Momose F, Sekimoto T, Ohkura T, Jo S, Kawaguchi A, Nagata K, et al. . Apical transport of influenza a virus ribonucleoprotein requires rab11-positive recycling endosome. PloS One. (2011) 6:e21123. doi: 10.1371/journal.pone.0021123</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021123</ArticleId><ArticleId IdType="pmc">PMC3120830</ArticleId><ArticleId IdType="pubmed">21731653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. (2005) 79:15511–24. doi: 10.1128/jvi.79.24.15511-15524.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.79.24.15511-15524.2005</ArticleId><ArticleId IdType="pmc">PMC1316022</ArticleId><ArticleId IdType="pubmed">16306622</ArticleId></ArticleIdList></Reference><Reference><Citation>Milewska A, Kula-Pacurar A, Wadas J, Suder A, Szczepanski A, Dabrowska A, et al. . Replication of severe acute respiratory syndrome coronavirus 2 in human respiratory epithelium. J Virol. (2020) 94:e00957-20. doi: 10.1128/JVI.00957-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00957-20</ArticleId><ArticleId IdType="pmc">PMC7375387</ArticleId><ArticleId IdType="pubmed">32434888</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyrc K, Sims AC, Dijkman R, Jebbink M, Long C, Deming D, et al. . Culturing the unculturable: human coronavirus hku1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J Virol. (2010) 84:11255–63. doi: 10.1128/JVI.00947-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00947-10</ArticleId><ArticleId IdType="pmc">PMC2953148</ArticleId><ArticleId IdType="pubmed">20719951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, Collins PL, et al. . Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol. (2005) 79:1113–24. doi: 10.1128/JVI.79.2.1113-1124.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.1113-1124.2005</ArticleId><ArticleId IdType="pmc">PMC538579</ArticleId><ArticleId IdType="pubmed">15613339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as covid-19 therapy. Adv Drug Delivery Rev. (2021) 169:100–17. doi: 10.1016/j.addr.2020.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.12.004</ArticleId><ArticleId IdType="pmc">PMC7833882</ArticleId><ArticleId IdType="pubmed">33309815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai SK, McSweeney MD, Pickles RJ. Learning from past failures: challenges with monoclonal antibody therapies for covid-19. J Control Release. (2021) 329:87–95. doi: 10.1016/j.jconrel.2020.11.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.11.057</ArticleId><ArticleId IdType="pmc">PMC7836766</ArticleId><ArticleId IdType="pubmed">33276017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. mAbs. (2022) 14:2014296. doi: 10.1080/19420862.2021.2014296</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2021.2014296</ArticleId><ArticleId IdType="pmc">PMC8765076</ArticleId><ArticleId IdType="pubmed">35030985</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfrey RWA. Human airway epithelial tight junctions. Microscopy Res Technique. (1997) 38:488–99. doi: 10.1002/(sici)1097-0029(19970901)38:5&lt;488::Aid-jemt5&gt;3.0.Co;2-e</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0029(19970901)38:5&lt;488::Aid-jemt5&gt;3.0.Co;2-e</ArticleId><ArticleId IdType="pubmed">9376652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima T, Go M, Takano K-I, Kurose M, Ohkuni T, Koizumi J-I, et al. . Regulation of tight junctions in upper airway epithelium. BioMed Res Int. (2013) 2013:1–11. doi: 10.1155/2013/947072</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/947072</ArticleId><ArticleId IdType="pmc">PMC3591135</ArticleId><ArticleId IdType="pubmed">23509817</ArticleId></ArticleIdList></Reference><Reference><Citation>Overgaard CE, Mitchell LA, Koval M. Roles for claudins in alveolar epithelial barrier function. Ann N Y Acad Sci. (2012) 1257:167–74. doi: 10.1111/j.1749-6632.2012.06545.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2012.06545.x</ArticleId><ArticleId IdType="pmc">PMC3375852</ArticleId><ArticleId IdType="pubmed">22671603</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidl S, Ellinger I, Niederberger V, Waltl EE, Fuchs R. Localization of the human neonatal fc receptor (Fcrn) in human nasal epithelium. Protoplasma. (2016) 253:1557–64. doi: 10.1007/s00709-015-0918-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00709-015-0918-y</ArticleId><ArticleId IdType="pubmed">26634928</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. . Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life. J Exp Med. (2002) 196:303–10. doi: 10.1084/jem.20020400</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20020400</ArticleId><ArticleId IdType="pmc">PMC2193935</ArticleId><ArticleId IdType="pubmed">12163559</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Ladinsky MS, Huey-Tubman KE, Jensen GJ, McIntosh JR, Björkman PJ. Fcrn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature. (2008) 455:542–6. doi: 10.1038/nature07255</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07255</ArticleId><ArticleId IdType="pmc">PMC2773227</ArticleId><ArticleId IdType="pubmed">18818657</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker K, Qiao S-W, Kuo T, Kobayashi K, Yoshida M, Lencer WI, et al. . Immune and non-immune functions of the (Not so) neonatal fc receptor, fcrn. Semin Immunopathology. (2009) 31:223–36. doi: 10.1007/s00281-009-0160-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-009-0160-9</ArticleId><ArticleId IdType="pmc">PMC3898171</ArticleId><ArticleId IdType="pubmed">19495758</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The neonatal fc receptor (Fcrn): A misnomer? Front Immunol. (2019) 10:1540. doi: 10.3389/fimmu.2019.01540</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01540</ArticleId><ArticleId IdType="pmc">PMC6636548</ArticleId><ArticleId IdType="pubmed">31354709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo TT, Baker K, Yoshida M, Qiao S-W, Aveson VG, Lencer WI, et al. . Neonatal fc receptor: from immunity to therapeutics. J Clin Immunol. (2010) 30:777–89. doi: 10.1007/s10875-010-9468-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-010-9468-4</ArticleId><ArticleId IdType="pmc">PMC2970823</ArticleId><ArticleId IdType="pubmed">20886282</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitcutt MJ, Adler KB, Wu R. A biphasic chamber system for maintaining polarity of differentiation of culture respiratory tract epithelial cells. In Vitro Cell Dev Biol. (1988) 24:420–8. doi: 10.1007/bf02628493</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf02628493</ArticleId><ArticleId IdType="pubmed">3372447</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaya M, Finkbeiner WE, Chun SY, Widdicombe JH. Differentiated structure and function of cultures from human tracheal epithelium. Am J Physiol. (1992) 262:L713–24. doi: 10.1152/ajplung.1992.262.6.L713</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.1992.262.6.L713</ArticleId><ArticleId IdType="pubmed">1616056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles RJ, McCarty D, Matsui H, Hart PDJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol. (1998) 72:6014–23. doi: 10.1128/jvi.72.7.6014-6023.1998</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.72.7.6014-6023.1998</ArticleId><ArticleId IdType="pmc">PMC110406</ArticleId><ArticleId IdType="pubmed">9621064</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of sars-cov-2 spike protein: potential antivirus drug development for covid-19. Acta Pharmacologica Sin. (2020) 41:1141–9. doi: 10.1038/s41401-020-0485-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. . Potently neutralizing and protective human antibodies against sars-cov-2. Nature. (2020) 584:443–9. doi: 10.1038/s41586-020-2548-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2548-6</ArticleId><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. . A highly potent extended half-life antibody as a potential rsv vaccine surrogate for all infants. Sci Transl Med. (2017) 9:eaaj1928. doi: 10.1126/scitranslmed.aaj1928</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaj1928</ArticleId><ArticleId IdType="pubmed">28469033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. . Cross-neutralization of sars-cov-2 by a human monoclonal sars-cov antibody. Nature. (2020) 583:290–5. doi: 10.1038/s41586-020-2349-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbie GJ, Criste R, Dall’Acqua WF, Jensen K, Patel NK, Losonsky GA, et al. . A novel investigational fc-modified humanized monoclonal antibody, motavizumab-yte, has an extended half-life in healthy adults. Antimicrobial Agents Chemotherapy. (2013) 57:6147–53. doi: 10.1128/aac.01285-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.01285-13</ArticleId><ArticleId IdType="pmc">PMC3837853</ArticleId><ArticleId IdType="pubmed">24080653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, et al. . Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. (2010) 28:157–9. doi: 10.1038/nbt.1601</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1601</ArticleId><ArticleId IdType="pmc">PMC2855492</ArticleId><ArticleId IdType="pubmed">20081867</ArticleId></ArticleIdList></Reference><Reference><Citation>Swope K, Morton J, Pogue GP, Burden L, Partain N, Hume S, et al. . Reproducibility and flexibility of monoclonal antibody production with nicotiana benthamiana . mAbs. (2022) 14:e2013594. doi: 10.1080/19420862.2021.2013594</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2021.2013594</ArticleId><ArticleId IdType="pmc">PMC8744878</ArticleId><ArticleId IdType="pubmed">35000569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. (2002) 76:5654–66. doi: 10.1128/jvi.76.11.5654-5666.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.11.5654-5666.2002</ArticleId><ArticleId IdType="pmc">PMC137037</ArticleId><ArticleId IdType="pubmed">11991994</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuda K, Dang H, Kobayashi Y, Carraro G, Nakano S, Chen G, et al. . Secretory cells dominate airway cftr expression and function in human airway superficial epithelia. Am J Respir Crit Care Med. (2021) 203:1275–89. doi: 10.1164/rccm.202008-3198oc</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202008-3198oc</ArticleId><ArticleId IdType="pmc">PMC8456462</ArticleId><ArticleId IdType="pubmed">33321047</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilho A, Bohorova N, Grass J, Bohorov O, Zeitlin L, Whaley K, et al. . Rapid high yield production of different glycoforms of ebola virus monoclonal antibody. PloS One. (2011) 6:e26040. doi: 10.1371/journal.pone.0026040</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026040</ArticleId><ArticleId IdType="pmc">PMC3200319</ArticleId><ArticleId IdType="pubmed">22039433</ArticleId></ArticleIdList></Reference><Reference><Citation>Whaley KJ, Hiatt A, Zeitlin L. Emerging antibody products and nicotiana manufacturing. Hum Vaccines. (2011) 7:349–56. doi: 10.4161/hv.7.3.14266</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.7.3.14266</ArticleId><ArticleId IdType="pmc">PMC3166493</ArticleId><ArticleId IdType="pubmed">21358287</ArticleId></ArticleIdList></Reference><Reference><Citation>Politch JA, Cu-Uvin S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, et al. . Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (Mb66): A phase I randomized trial. PloS Med. (2021) 18:e1003495. doi: 10.1371/journal.pmed.1003495</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003495</ArticleId><ArticleId IdType="pmc">PMC7857576</ArticleId><ArticleId IdType="pubmed">33534791</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. . A randomized, controlled trial of ebola virus disease therapeutics. New Engl J Med. (2019) 381:2293–303. doi: 10.1056/nejmoa1910993</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1910993</ArticleId><ArticleId IdType="pmc">PMC10680050</ArticleId><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, et al. . Pharmacokinetics and pharmacodynamics of abelacimab (Maa868), a novel dual inhibitor of factor xi and factor xia. J Thromb Haemostasis. (2022) 20:307–15. doi: 10.1111/jth.15577</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15577</ArticleId><ArticleId IdType="pmc">PMC9298689</ArticleId><ArticleId IdType="pubmed">34714969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou B, Wei H, Yang F, Wang S, Yang B, Zheng Y, et al. . Preclinical characterization of gls-010 (Zimberelimab), a novel fully human anti-pd-1 therapeutic monoclonal antibody for cancer. Front Oncol. (2021) 11:736955. doi: 10.3389/fonc.2021.736955</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.736955</ArticleId><ArticleId IdType="pmc">PMC8479189</ArticleId><ArticleId IdType="pubmed">34604074</ArticleId></ArticleIdList></Reference><Reference><Citation>Chastre J, François B, Bourgeois M, Komnos A, Ferrer R, Rahav G, et al. . Safety, efficacy, and pharmacokinetics of gremubamab (Medi3902), an anti-pseudomonas aeruginosa bispecific human monoclonal antibody, in P. Aeruginosa-colonised, mechanically ventilated intensive care unit patients: A randomised controlled trial. Crit Care. (2022) 26:355. doi: 10.1186/s13054-022-04204-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04204-9</ArticleId><ArticleId IdType="pmc">PMC9666938</ArticleId><ArticleId IdType="pubmed">36380312</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. (2011) 50:215–27. doi: 10.2165/11584340-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11584340-000000000-00000</ArticleId><ArticleId IdType="pubmed">21348536</ArticleId></ArticleIdList></Reference><Reference><Citation>Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, et al. . The underlying inflammatory chronic disease influences infliximab pharmacokinetics. mAbs. (2016) 8:1407–16. doi: 10.1080/19420862.2016.1216741</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2016.1216741</ArticleId><ArticleId IdType="pmc">PMC5058621</ArticleId><ArticleId IdType="pubmed">27589009</ArticleId></ArticleIdList></Reference><Reference><Citation>Moench TR, Botta L, Farrer B, Lickliter JD, Kang H, Park Y, et al. . A randomized, double-blind, phase 1 study of in-006, an inhaled antibody treatment for covid-19. MedRxiv. (2022). doi: 10.1101/2022.08.17.22278748</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.17.22278748</ArticleId></ArticleIdList></Reference><Reference><Citation>Streblow DN, Hirsch AJ, Stanton JJ, Lewis AD, Colgin L, Hessell AJ, et al. . Aerosol delivery of sars-cov-2 human monoclonal antibodies in macaques limits viral replication and lung pathology. Nat Commun. (2023) 14:7062. doi: 10.1038/s41467-023-42440-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42440-x</ArticleId><ArticleId IdType="pmc">PMC10624670</ArticleId><ArticleId IdType="pubmed">37923717</ArticleId></ArticleIdList></Reference><Reference><Citation>McSweeney MD, Alnajjar S, Schaefer AM, Richardson Z, Wolf W, Stewart I, et al. . Inhaled “Muco-trapping” Monoclonal antibody effectively treats established respiratory syncytial virus (Rsv) infections. Adv Sci (Weinh). (2024) 11:e2306729. doi: 10.1002/advs.202306729</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202306729</ArticleId><ArticleId IdType="pmc">PMC10966576</ArticleId><ArticleId IdType="pubmed">38225749</ArticleId></ArticleIdList></Reference><Reference><Citation>Copin R, Baum A, Wloga E, Pascal KE, Giordano S, Fulton BO, et al. . The monoclonal antibody combination regen-cov protects against sars-cov-2 mutational escape in preclinical and human studies. Cell. (2021) 184:3949–61 e11. doi: 10.1016/j.cell.2021.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8179113</ArticleId><ArticleId IdType="pubmed">34161776</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. . Bamlanivimab plus etesevimab in mild or moderate covid-19. New Engl J Med. (2021) 385:1382–92. doi: 10.1056/nejmoa2102685</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2102685</ArticleId><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ryu D-K, Lee J, Kim Y-I, Seo J-M, Kim Y-G, et al. . A therapeutic neutralizing antibody targeting receptor binding domain of sars-cov-2 spike protein. Nat Commun. (2021) 12:288. doi: 10.1038/s41467-020-20602-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20602-5</ArticleId><ArticleId IdType="pmc">PMC7803729</ArticleId><ArticleId IdType="pubmed">33436577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekiert DC, Friesen RHE, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. . A highly conserved neutralizing epitope on group 2 influenza a viruses. Science. (2011) 333:843–50. doi: 10.1126/science.1204839</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1204839</ArticleId><ArticleId IdType="pmc">PMC3210727</ArticleId><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, et al. . Structure and function analysis of an antibody recognizing all influenza a subtypes. Cell. (2016) 166:596–608. doi: 10.1016/j.cell.2016.05.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.073</ArticleId><ArticleId IdType="pmc">PMC4967455</ArticleId><ArticleId IdType="pubmed">27453466</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, et al. . An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza a antibodies. Cell Host Microbe. (2013) 14:93–103. doi: 10.1016/j.chom.2013.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2013.06.004</ArticleId><ArticleId IdType="pubmed">23870317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discovery. (2010) 9:325–38. doi: 10.1038/nrd3003</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3003</ArticleId><ArticleId IdType="pubmed">20305665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Lai H, Na F, Li S, Qiu X, Tian J, et al. . Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children. JAMA Network Open. (2023) 6:e230023. doi: 10.1001/jamanetworkopen.2023.0023</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.0023</ArticleId><ArticleId IdType="pmc">PMC9938429</ArticleId><ArticleId IdType="pubmed">36800182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence SA, Blankenship R, Brown R, Estwick S, Ellis B, Thangaraju A, et al. . Influence of fcrn binding properties on the gastrointestinal absorption and exposure profile of fc molecules. Bioorg Med Chem. (2021) 32:115942. doi: 10.1016/j.bmc.2020.115942</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2020.115942</ArticleId><ArticleId IdType="pubmed">33461147</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, et al. . Enhanced fcrn-dependent transepithelial delivery of igg by fc-engineering and polymerization. J Control Release. (2016) 223:42–52. doi: 10.1016/j.jconrel.2015.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.12.033</ArticleId><ArticleId IdType="pubmed">26718855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bequignon E, Dhommée C, Angely C, Thomas L, Bottier M, Escudier E, et al. . Fcrn-dependent transcytosis of monoclonal antibody in human nasal epithelial cells in vitro: A prerequisite for a new delivery route for therapy? Int J Mol Sci. (2019) 20:1379. doi: 10.3390/ijms20061379</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061379</ArticleId><ArticleId IdType="pmc">PMC6470570</ArticleId><ArticleId IdType="pubmed">30893823</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez Ledo A, Dimke T, Tschantz WR, Rowlands D, Growcott E. The role of airway mucus and diseased pulmonary epithelium on the absorption of inhaled antibodies. Int J Pharm. (2023) 647:123519. doi: 10.1016/j.ijpharm.2023.123519</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2023.123519</ArticleId><ArticleId IdType="pubmed">37852310</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall’Acqua WF, Kiener PA, Wu H. Properties of human igg1s engineered for enhanced binding to the neonatal fc receptor (Fcrn). J Biol Chem. (2006) 281:23514–24. doi: 10.1074/jbc.m604292200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.m604292200</ArticleId><ArticleId IdType="pubmed">16793771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor A, Thibert B, Huille S, Respaud R, Audat H, Heuzé-Vourc’H N. Inhaled antibodies: formulations require specific development to overcome instability due to nebulization. Drug Delivery Trans Res. (2021) 11:1625–33. doi: 10.1007/s13346-021-00967-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-021-00967-w</ArticleId><ArticleId IdType="pmc">PMC7993445</ArticleId><ArticleId IdType="pubmed">33768475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodier-Montagutelli E, Respaud R, Perret G, Baptista L, Duquenne P, Heuze-Vourc’h N, et al. . Protein stability during nebulization: mind the collection step! Eur J Pharm Biopharm. (2020) 152:23–34. doi: 10.1016/j.ejpb.2020.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2020.04.006</ArticleId><ArticleId IdType="pubmed">32289493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis RA, Fleming JS. Fractional deposition from a jet nebulizer: how it differs from a metered dose inhaler. Br J Dis Chest. (1985) 79:361–7. doi: 10.1016/0007-0971(85)90069-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0007-0971(85)90069-5</ArticleId><ArticleId IdType="pubmed">4052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven RW, Ip AY, Mittelman S, Prestrelski SJ, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res. (1995) 12:53–9. doi: 10.1023/a:1016282502954</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1016282502954</ArticleId><ArticleId IdType="pubmed">7724488</ArticleId></ArticleIdList></Reference><Reference><Citation>McSweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C, et al. . Stable nebulization and muco-trapping properties of regdanvimab/in-006 support its development as a potent, dose-saving inhaled therapy for covid-19. Bioengineering Trans Med. (2023) 8:e10391. doi: 10.1002/btm2.10391</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10391</ArticleId><ArticleId IdType="pmc">PMC9537933</ArticleId><ArticleId IdType="pubmed">36248234</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiruthani K, Cruz-Teran C, Chan JFW, Ma A, McSweeney M, Wolf W, et al. . Engineering a “Muco-trapping” Ace2-immunoglobulin hybrid with picomolar affinity as an inhaled, pan-variant immunotherapy for covid-19. Bioengineering Trans Med. (2024) 9:e10650. doi: 10.1002/btm2.10650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10650</ArticleId><ArticleId IdType="pmc">PMC11256170</ArticleId><ArticleId IdType="pubmed">39036085</ArticleId></ArticleIdList></Reference><Reference><Citation>Respaud R, Vecellio L, Diot P, Heuze-Vourc’h N. Nebulization as a delivery method for mabs in respiratory diseases. Expert Opin Drug Delivery. (2015) 12:1027–39. doi: 10.1517/17425247.2015.999039</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2015.999039</ArticleId><ArticleId IdType="pubmed">25557066</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>